GenScript ProBio Extends Congratulations to InnoBation Bio on MFDS Clearance
GenScript, GenScript Pro, and Legend Biotech Will Attend the 42nd JPM Conference
GenScript ProBio Partners With NuclixBio to Pave the Way for South Korea’s First Large-scale Production Process for “Circular RNA Therapeutics”
PISCATAWAY, N.J. & NEW YORK--(BUSINESS WIRE)--GenScript ProBio, a global contract development and manufacturing organization, and Comprehensive Cell Solutions (CCS), a leader in cell therapy development and manufacturing, have partnered to spearhead the development of cell and gene therapies, offering a unique and seamlessly integrated solution that spans cell collections and apheresis through cryopreservation of final therapeutics.
Recently, Eutilex, a partner of GenScript ProBio, announced MFDS clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio extends congratulations on this. 2 years ago, GenScript ProBio and Eutilex announced that the parties entered into strategic collaboration on plasmid and virus process development and manufacturing for multiple CAR-T programs.
GenScript Biotech Corp., a provider of life-science research tools and services, has expanded its Singapore facility to provide a premium gene synthesis service.
GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), and RVAC Medicines Pte. Ltd., a biotechnology company focusing on the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines, entered a strategic partnership for the manufacturing of GMP-grade plasmid DNA (pDNA) for its mRNA COVID-19 vaccine candidate, RVM-V001, along with collaboration for future therapeutic pipelines.
GenScript ProBio, a biologics contract development and manufacturing organization (CDMO) to the biopharmaceutical market, and Bio Immunitas, a UK pharmaceutical company with a novel, safe and efficacious human Recombinant Protein Platform (hRPP), announced a partnership for developing potential novel therapies for clinical use.
China’s GenScript has brought in new investors to back its biologics-focused subsidiary — to the tune of $224 million.